Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc. (HALO)
Filing Type: Form 8-K (Current Report)
Date of Report: February 22, 2022
Reporting Period: Fourth Quarter ended December 31, 2021
This filing serves as a notification that the company issued a press release on February 22, 2022, reporting its financial results for the fourth quarter of 2021. The press release is attached as Exhibit 99.1.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It solely references the issuance of the Q4 2021 results press release.
Guidance, Outlook, and Risks
Guidance and Outlook: No specific guidance or outlook is provided in this filing text; such information would be located in the attached press release.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Unusual Items: None reported in this filing text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q4 2021 financial figures (revenue, net income, cash position).
- Verify the company's forward-looking statements and guidance provided in the press release.
- Confirm the status of the company's cash runway and burn rate as detailed in the full financial report.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.